A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.

Fiche publication

Date publication

mai 2024

Journal

Journal of experimental & clinical cancer research : CR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen , Dr JEGO Gaëtan , Dr DUPLOMB-JEGO Laurence

Tous les auteurs :
Durand M, Cabaud Gibouin V, Duplomb L, Salmi L, Caillot M, Sola B, Camus V, Jardin F, Garrido C, Jego G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38773631

Résumé

Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor development due to multiple recurrent mutations, particularly in STAT6. Furthermore, the XPO1 gene that encodes exportin 1 (XPO1) shows a frequent point mutation (E571K) resulting in an altered export of hundreds of cargo proteins, which may impact the success of future therapies in PMBL and cHL. Therefore, targeted therapies have been envisioned for these signaling pathways and mutations.